Please try another search
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Michael Stephen Wyzga | 66 | 2018 | Independent Chairman of the Board |
Rene Russo | 46 | 2019 | Director |
Paula Ragan | 53 | 2014 | CEO, President & Director |
Francoise de Craecker | 61 | 2021 | Independent Director |
Keith T. Flaherty | 52 | 2016 | Founder & Member of Corporate Advisory Board |
David W. J. McGirr | 69 | 2017 | Independent Director |
R. Keith Woods | 55 | 2023 | Independent Director |
Alison F. Lawton | 63 | 2016 | Independent Director |
Michael J. Vasconcelles | 61 | 2016 | Member of Corporate Advisory Board |
William E. Aliski | 78 | 2019 | Independent Director |
Murray W. Stewart | 62 | 2019 | Director |
Gary J. Bridger | 61 | 2019 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review